Unknown

Dataset Information

0

Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.


ABSTRACT: BACKGROUND:The role of the antiviral therapy in treatment of COVID-19 is still a matter to be investigated. Also efficacy and safety of antiviral regimens were not compared according severity of the disease. In this study the efficacy and safety of hydroxychloroquine plus atazanavir/ritonavir was compared in patients with moderate and severe COVID-19. METHODS:We prospectively evaluated the clinical outcomes of 213 patients with COVID-19 during the hospitalization course and up to 56 days after the hospital discharge. The disease was categorized to moderate and severe based on the severity of pneumonia and peripheral oxygen saturation (SpO2). The patients received the national treatment protocol containing hydroxychloroquine (400 mg BD in first day and then 200 mg BD) plus atazanavir/ritonavir (300/100 mg daily) for 7 days. Main outcomes included discharge rates at day 7, 14 and 28, 28-day mortality, rate of intensive care unit (ICU) admission and intubation, length of hospital and ICU stay and incidence of adverse events. RESULTS:The mean (SD) age of patients was 60(14) years and 53% were male. According to WHO definition, 51.64% and 48.36% of the patients had moderate (SpO2???90%) and severe disease (SpO2?

SUBMITTER: Rahmani H 

PROVIDER: S-EPMC7453126 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.

Rahmani Hamid H   Davoudi-Monfared Effat E   Nourian Anahid A   Nabiee Morteza M   Sadeghi Setayesh S   Khalili Hossein H   Abbasian Ladan L   Ghiasvand Fereshteh F   Seifi Arash A   Hasannezhad Malihe M   Ghaderkhani Sara S   Mohammadi Mostafa M   Yekaninejad Mir Saeed MS  

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20200828 2


<h4>Background</h4>The role of the antiviral therapy in treatment of COVID-19 is still a matter to be investigated. Also efficacy and safety of antiviral regimens were not compared according severity of the disease. In this study the efficacy and safety of hydroxychloroquine plus atazanavir/ritonavir was compared in patients with moderate and severe COVID-19.<h4>Methods</h4>We prospectively evaluated the clinical outcomes of 213 patients with COVID-19 during the hospitalization course and up to  ...[more]

Similar Datasets

| S-EPMC3905755 | biostudies-literature
| S-EPMC3165362 | biostudies-literature
| S-EPMC8149166 | biostudies-literature
| S-EPMC4577040 | biostudies-literature
| S-EPMC8100580 | biostudies-literature
| S-EPMC3430716 | biostudies-literature
| S-EPMC7121492 | biostudies-literature
| S-EPMC2680942 | biostudies-literature